Frequency of peripheral neuropathy and injection site reactions in patients with multiple myeloma receiving subcutaneous versus intravenous bortezomib
Multiple myeloma is an incurable hematological malignancy with patients living on average 3 to 6 years after diagnosis. Bortezomib is widely used to treat multiple myeloma. Peripheral neuropathy has been a major side effect associated with bortezomib treatment, and occurs in 47% to 64% of patients....
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2015
|
| Online Access: | http://hdl.handle.net/2429/52695 |